US798959A
(en)
|
1904-12-19 |
1905-09-05 |
George W Goss |
Corn-husker.
|
IL47062A
(en)
|
1975-04-10 |
1979-07-25 |
Yeda Res & Dev |
Process for diminishing antigenicity of tissues to be usedas transplants by treatment with glutaraldehyde
|
US4665077A
(en)
|
1979-03-19 |
1987-05-12 |
The Upjohn Company |
Method for treating rejection of organ or skin grafts with 6-aryl pyrimidine compounds
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
US5807715A
(en)
|
1984-08-27 |
1998-09-15 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
|
US4676980A
(en)
|
1985-09-23 |
1987-06-30 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Target specific cross-linked heteroantibodies
|
US6548640B1
(en)
|
1986-03-27 |
2003-04-15 |
Btg International Limited |
Altered antibodies
|
IL85035A0
(en)
|
1987-01-08 |
1988-06-30 |
Int Genetic Eng |
Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
|
JP3101690B2
(ja)
|
1987-03-18 |
2000-10-23 |
エス・ビィ・2・インコーポレイテッド |
変性抗体の、または変性抗体に関する改良
|
IL85746A
(en)
|
1988-03-15 |
1994-05-30 |
Yeda Res & Dev |
Preparations comprising t-lymphocyte cells treated with 8-methoxypsoralen or cell membranes separated therefrom for preventing or treating autoimmune diseases
|
FI891226A
(fi)
|
1988-04-28 |
1989-10-29 |
Univ Leland Stanford Junior |
Reseptordeterminanter i anti-t-celler foer behandling av autoimmunsjukdom.
|
EP0368684B2
(en)
|
1988-11-11 |
2004-09-29 |
Medical Research Council |
Cloning immunoglobulin variable domain sequences.
|
WO1990008187A1
(en)
|
1989-01-19 |
1990-07-26 |
Dana Farber Cancer Institute |
Soluble two domain cd2 protein
|
EP0463101B2
(en)
|
1989-03-21 |
2003-03-19 |
The Immune Response Corporation |
Vaccination and methods against diseases resulting from pathogenic responses by specific t cell populations
|
DE3920358A1
(de)
|
1989-06-22 |
1991-01-17 |
Behringwerke Ag |
Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
|
AU652540B2
(en)
|
1989-07-19 |
1994-09-01 |
Xoma Corporation |
T cell receptor peptides as therapeutics for autoimmune and malignant disease
|
WO1991002536A1
(en)
|
1989-08-23 |
1991-03-07 |
Scripps Clinic And Research Foundation |
Compositions and methods for detection and treatment of epstein-barr virus infection and immune disorders
|
US5208020A
(en)
|
1989-10-25 |
1993-05-04 |
Immunogen Inc. |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
US5959177A
(en)
|
1989-10-27 |
1999-09-28 |
The Scripps Research Institute |
Transgenic plants expressing assembled secretory antibodies
|
US6075181A
(en)
|
1990-01-12 |
2000-06-13 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
US6150584A
(en)
|
1990-01-12 |
2000-11-21 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
JPH053790A
(ja)
|
1990-04-19 |
1993-01-14 |
Fujisawa Pharmaceut Co Ltd |
デヒドロペプチダーゼ−i
|
US5256643A
(en)
|
1990-05-29 |
1993-10-26 |
The Government Of The United States |
Human cripto protein
|
US5770429A
(en)
|
1990-08-29 |
1998-06-23 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
WO1992007574A1
(en)
|
1990-10-25 |
1992-05-14 |
Tanox Biosystems, Inc. |
Glycoproteins associated with membrane-bound immunoglobulins as antibody targets on b cells
|
DK0564531T3
(da)
|
1990-12-03 |
1998-09-28 |
Genentech Inc |
Berigelsesfremgangsmåde for variantproteiner med ændrede bindingsegenskaber
|
US5571894A
(en)
|
1991-02-05 |
1996-11-05 |
Ciba-Geigy Corporation |
Recombinant antibodies specific for a growth factor receptor
|
US5543503A
(en)
|
1991-03-29 |
1996-08-06 |
Genentech Inc. |
Antibodies to human IL-8 type A receptor
|
US5440021A
(en)
|
1991-03-29 |
1995-08-08 |
Chuntharapai; Anan |
Antibodies to human IL-8 type B receptor
|
WO1992017497A1
(en)
|
1991-03-29 |
1992-10-15 |
Genentech, Inc. |
Human pf4a receptors and their use
|
LU91067I2
(fr)
|
1991-06-14 |
2004-04-02 |
Genentech Inc |
Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines
|
GB9114948D0
(en)
|
1991-07-11 |
1991-08-28 |
Pfizer Ltd |
Process for preparing sertraline intermediates
|
JP3050424B2
(ja)
|
1991-07-12 |
2000-06-12 |
塩野義製薬株式会社 |
ヒトエンドセリンリセプター
|
US5264557A
(en)
|
1991-08-23 |
1993-11-23 |
The United States Of America As Represented By The Department Of Health And Human Services |
Polypeptide of a human cripto-related gene, CR-3
|
CA2116774C
(en)
|
1991-09-19 |
2003-11-11 |
Paul J. Carter |
Expression in e. coli antibody fragments having at least a cysteine present as a free thiol. use for the production of bifunctional f(ab') 2 antibodies
|
US5587458A
(en)
|
1991-10-07 |
1996-12-24 |
Aronex Pharmaceuticals, Inc. |
Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
|
WO1993008829A1
(en)
|
1991-11-04 |
1993-05-13 |
The Regents Of The University Of California |
Compositions that mediate killing of hiv-infected cells
|
US6153408A
(en)
|
1991-11-15 |
2000-11-28 |
Institut Pasteur And Institut National De La Sante Et De La Recherche Medicale |
Altered major histocompatibility complex (MHC) determinant and methods of using the determinant
|
US5976551A
(en)
|
1991-11-15 |
1999-11-02 |
Institut Pasteur And Institut Nationale De La Sante Et De La Recherche Medicale |
Altered major histocompatibility complex (MHC) determinant and method of using the determinant
|
CA2372813A1
(en)
|
1992-02-06 |
1993-08-19 |
L.L. Houston |
Biosynthetic binding protein for cancer marker
|
IL107366A
(en)
|
1992-10-23 |
2003-03-12 |
Chugai Pharmaceutical Co Ltd |
Genes coding for megakaryocyte potentiator
|
US5644033A
(en)
|
1992-12-22 |
1997-07-01 |
Health Research, Inc. |
Monoclonal antibodies that define a unique antigen of human B cell antigen receptor complex and methods of using same for diagnosis and treatment
|
US5801005A
(en)
|
1993-03-17 |
1998-09-01 |
University Of Washington |
Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
|
US5869445A
(en)
|
1993-03-17 |
1999-02-09 |
University Of Washington |
Methods for eliciting or enhancing reactivity to HER-2/neu protein
|
US6214345B1
(en)
|
1993-05-14 |
2001-04-10 |
Bristol-Myers Squibb Co. |
Lysosomal enzyme-cleavable antitumor drug conjugates
|
WO1994029351A2
(en)
|
1993-06-16 |
1994-12-22 |
Celltech Limited |
Antibodies
|
US5773223A
(en)
|
1993-09-02 |
1998-06-30 |
Chiron Corporation |
Endothelin B1, (ETB1) receptor polypeptide and its encoding nucleic acid methods, and uses thereof
|
US5770377A
(en)
|
1994-07-20 |
1998-06-23 |
University Of Dundee |
Interruption of binding of MDM2 and P53 protein and therapeutic application thereof
|
US5750370A
(en)
|
1995-06-06 |
1998-05-12 |
Human Genome Sciences, Inc. |
Nucleic acid encoding human endothlein-bombesin receptor and method of producing the receptor
|
US5789199A
(en)
|
1994-11-03 |
1998-08-04 |
Genentech, Inc. |
Process for bacterial production of polypeptides
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
US5840523A
(en)
|
1995-03-01 |
1998-11-24 |
Genetech, Inc. |
Methods and compositions for secretion of heterologous polypeptides
|
US5869046A
(en)
|
1995-04-14 |
1999-02-09 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
US5707829A
(en)
|
1995-08-11 |
1998-01-13 |
Genetics Institute, Inc. |
DNA sequences and secreted proteins encoded thereby
|
US20020193567A1
(en)
|
1995-08-11 |
2002-12-19 |
Genetics Institute, Inc. |
Secreted proteins and polynucleotides encoding them
|
FR2738151B1
(fr)
|
1995-09-04 |
1997-09-26 |
Rhone Poulenc Rorer Sa |
Antagonistes de l'activite oncogenique de la proteine mdm2, et leur utilisation dans le traitement des cancers
|
GB9603256D0
(en)
|
1996-02-16 |
1996-04-17 |
Wellcome Found |
Antibodies
|
JP3646191B2
(ja)
|
1996-03-19 |
2005-05-11 |
大塚製薬株式会社 |
ヒト遺伝子
|
CZ365098A3
(cs)
|
1996-05-17 |
1999-06-16 |
Schering Corporation |
Izolovaná a rekombinovaná nukleová kyselina, BAS-1 protein nebo jeho peptid a prostředek, protilátka, expresní vektor, hostitelská buňka a způsoby jejich použití
|
JP2001500365A
(ja)
|
1996-07-05 |
2001-01-16 |
ノバルティス アクチエンゲゼルシャフト |
P53とmdm2の間の相互作用の阻害剤
|
US5945511A
(en)
|
1997-02-20 |
1999-08-31 |
Zymogenetics, Inc. |
Class II cytokine receptor
|
US7033827B2
(en)
|
1997-02-25 |
2006-04-25 |
Corixa Corporation |
Prostate-specific polynucleotide compositions
|
US20030185830A1
(en)
|
1997-02-25 |
2003-10-02 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of prostate cancer
|
US6541212B2
(en)
|
1997-03-10 |
2003-04-01 |
The Regents Of The University Of California |
Methods for detecting prostate stem cell antigen protein
|
US6261791B1
(en)
|
1997-03-10 |
2001-07-17 |
The Regents Of The University Of California |
Method for diagnosing cancer using specific PSCA antibodies
|
NZ337413A
(en)
|
1997-03-10 |
2003-02-28 |
Univ California |
Antibodies that bind to Prostate Stem Cell Antigen (PSCA) to treat prostate cancer.
|
US6555339B1
(en)
|
1997-04-14 |
2003-04-29 |
Arena Pharmaceuticals, Inc. |
Non-endogenous, constitutively activated human protein-coupled receptors
|
US6319688B1
(en)
|
1997-04-28 |
2001-11-20 |
Smithkline Beecham Corporation |
Polynucleotide encoding human sodium dependent phosphate transporter (IPT-1)
|
DK0979281T3
(da)
|
1997-05-02 |
2005-11-21 |
Genentech Inc |
Fremgangsmåde til fremstilling af multispecifikke antistoffer med heteromultimere og fælles bestanddele
|
WO1998051824A1
(en)
|
1997-05-15 |
1998-11-19 |
Abbott Laboratories |
Reagents and methods useful for detecting disease of the urinary tract
|
US6890749B2
(en)
|
1997-05-15 |
2005-05-10 |
Abbott Laboratories |
Reagents and methods useful for detecting diseases of the prostate
|
WO1998058964A1
(en)
|
1997-06-24 |
1998-12-30 |
Genentech, Inc. |
Methods and compositions for galactosylated glycoproteins
|
US6040498A
(en)
|
1998-08-11 |
2000-03-21 |
North Caroline State University |
Genetically engineered duckweed
|
US20030060612A1
(en)
|
1997-10-28 |
2003-03-27 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
WO1999022764A1
(en)
|
1997-10-31 |
1999-05-14 |
Genentech, Inc. |
Methods and compositions comprising glycoprotein glycoforms
|
US20020034749A1
(en)
|
1997-11-18 |
2002-03-21 |
Billing-Medel Patricia A. |
Reagents and methods useful for detecting diseases of the breast
|
US6610833B1
(en)
|
1997-11-24 |
2003-08-26 |
The Institute For Human Genetics And Biochemistry |
Monoclonal human natural antibodies
|
US6110695A
(en)
|
1997-12-02 |
2000-08-29 |
The Regents Of The University Of California |
Modulating the interaction of the chemokine, B Lymphocyte Hemoattractant, and its Receptor, BLR1
|
IL136544A0
(en)
|
1997-12-05 |
2001-06-14 |
Scripps Research Inst |
Humanization of murine antibody
|
ATE407943T1
(de)
|
1998-03-13 |
2008-09-15 |
Burnham Inst |
Zielsuchende verbindungen für verschiedene organe und gewebe
|
CA2323757C
(en)
|
1998-04-02 |
2011-08-02 |
Genentech, Inc. |
Antibody variants and fragments thereof
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
DK1071700T3
(da)
|
1998-04-20 |
2010-06-07 |
Glycart Biotechnology Ag |
Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
|
DE19820190A1
(de)
|
1998-04-28 |
1999-11-04 |
Metagen Gesellschaft Fuer Genomforschung Mbh |
Menschliche Nukleinsäuresequenzen aus Pankreas-Tumor
|
EP1078092B1
(en)
|
1998-05-13 |
2011-08-03 |
Epimmune Inc. |
Expression vectors for stimulating an immune response and methods of using the same
|
US20020187472A1
(en)
|
2001-03-09 |
2002-12-12 |
Preeti Lal |
Steap-related protein
|
US20030064397A1
(en)
|
1998-05-22 |
2003-04-03 |
Incyte Genomics, Inc. |
Transmembrane protein differentially expressed in prostate and lung tumors
|
WO2000012130A1
(en)
|
1998-08-27 |
2000-03-09 |
Smithkline Beecham Corporation |
Rp105 agonists and antagonists
|
JP4689781B2
(ja)
|
1998-09-03 |
2011-05-25 |
独立行政法人科学技術振興機構 |
アミノ酸輸送蛋白及びその遺伝子
|
GB9819860D0
(en)
|
1998-09-12 |
1998-11-04 |
Zeneca Ltd |
Chemical compounds
|
AU5963699A
(en)
|
1998-10-02 |
2000-04-26 |
Mcmaster University |
Spliced form of (erb)b-2/neu oncogene
|
WO2001057188A2
(en)
|
2000-02-03 |
2001-08-09 |
Hyseq, Inc. |
Novel nucleic acids and polypeptides
|
US6468546B1
(en)
|
1998-12-17 |
2002-10-22 |
Corixa Corporation |
Compositions and methods for therapy and diagnosis of ovarian cancer
|
US20030091580A1
(en)
|
2001-06-18 |
2003-05-15 |
Mitcham Jennifer L. |
Compositions and methods for the therapy and diagnosis of ovarian cancer
|
US6962980B2
(en)
|
1999-09-24 |
2005-11-08 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of ovarian cancer
|
US6858710B2
(en)
|
1998-12-17 |
2005-02-22 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of ovarian cancer
|
US20020119158A1
(en)
|
1998-12-17 |
2002-08-29 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of ovarian cancer
|
ATE407949T1
(de)
|
1998-12-30 |
2008-09-15 |
Beth Israel Hospital |
Charakterisierung der proteinfamilie von soc/crac kalziumkanälen
|
US20030190669A1
(en)
|
1998-12-30 |
2003-10-09 |
Genentech, Inc. |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
EP1141024B1
(en)
|
1999-01-15 |
2018-08-08 |
Genentech, Inc. |
POLYPEPTIDE COMPRISING A VARIANT HUMAN IgG1 Fc REGION
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
ES2348708T3
(es)
|
1999-01-29 |
2010-12-13 |
Corixa Corporation |
Proteinas de fusion de her-2/neu.
|
GB9905124D0
(en)
|
1999-03-05 |
1999-04-28 |
Smithkline Beecham Biolog |
Novel compounds
|
AU3395900A
(en)
|
1999-03-12 |
2000-10-04 |
Human Genome Sciences, Inc. |
Human lung cancer associated gene sequences and polypeptides
|
DK2270150T4
(da)
|
1999-04-09 |
2019-08-26 |
Kyowa Hakko Kirin Co Ltd |
Fremgangsmåde til at kontrollere aktiviteten af immunologisk funktionelt molekyle.
|
US7312303B2
(en)
|
1999-05-11 |
2007-12-25 |
Genentech, Inc. |
Anti-PRO4980 antibodies
|
WO2000075655A1
(fr)
|
1999-06-03 |
2000-12-14 |
Takeda Chemical Industries, Ltd. |
Procede de criblage avec cd100
|
US6949245B1
(en)
|
1999-06-25 |
2005-09-27 |
Genentech, Inc. |
Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
|
JP4780633B2
(ja)
|
1999-06-25 |
2011-09-28 |
イムノゲン インコーポレーティッド |
抗−ErbB抗体−メイタンシノイド複合体を用いた治療方法
|
US20030119113A1
(en)
|
1999-07-20 |
2003-06-26 |
Genentech, Inc. |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
US7297770B2
(en)
|
1999-08-10 |
2007-11-20 |
Genentech, Inc. |
PRO6496 polypeptides
|
US7294696B2
(en)
|
1999-08-17 |
2007-11-13 |
Genentech Inc. |
PRO7168 polypeptides
|
AU7573000A
(en)
|
1999-09-01 |
2001-03-26 |
Genentech Inc. |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
US20030232056A1
(en)
|
1999-09-10 |
2003-12-18 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of ovarian cancer
|
US20030206918A1
(en)
|
1999-09-10 |
2003-11-06 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of ovarian cancer
|
US20030129192A1
(en)
|
1999-09-10 |
2003-07-10 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of ovarian cancer
|
US7125978B1
(en)
|
1999-10-04 |
2006-10-24 |
Medicago Inc. |
Promoter for regulating expression of foreign genes
|
MXPA02003456A
(es)
|
1999-10-04 |
2002-10-23 |
Medicago Inc |
Metodo para regular la transcripcion de genes foraneos.
|
US6750054B2
(en)
|
2000-05-18 |
2004-06-15 |
Lexicon Genetics Incorporated |
Human semaphorin homologs and polynucleotides encoding the same
|
CA2388245C
(en)
|
1999-10-19 |
2012-01-10 |
Tatsuya Ogawa |
The use of serum-free adapted rat cells for producing heterologous polypeptides
|
DE60039448D1
(de)
|
1999-10-29 |
2008-08-21 |
Genentech Inc |
Gegen das prostata-stammzellantigen (psca) gerichtete antikörper und deren verwendung
|
AU2048901A
(en)
|
1999-11-29 |
2001-06-04 |
Trustees Of Columbia University In The City Of New York, The |
Isolation of five novel genes coding for new Fc receptors-type melanoma involved in the pathogenesis of lymphoma/melanoma
|
WO2001040269A2
(en)
|
1999-11-30 |
2001-06-07 |
Corixa Corporation |
Compositions and methods for therapy and diagnosis of breast cancer
|
JP2003530083A
(ja)
|
1999-12-10 |
2003-10-14 |
エピミューン インコーポレイテッド |
ペプチドおよび核酸組成物を使用する、HER2/neuに対する細胞性免疫応答の誘導
|
EP1240319A1
(en)
|
1999-12-15 |
2002-09-18 |
Genentech, Inc. |
Shotgun scanning, a combinatorial method for mapping functional protein epitopes
|
AU2458001A
(en)
|
1999-12-23 |
2001-07-03 |
Zymogenetics Inc. |
Method for treating inflammation
|
NZ502058A
(en)
|
1999-12-23 |
2003-11-28 |
Ovita Ltd |
Isolated mutated nucleic acid molecule for regulation of ovulation rate
|
DE60045139D1
(de)
|
1999-12-23 |
2010-12-02 |
Zymogenetics Inc |
Löslicher Interleukin-20-Rezeptor
|
US6610286B2
(en)
|
1999-12-23 |
2003-08-26 |
Zymogenetics, Inc. |
Method for treating inflammation using soluble receptors to interleukin-20
|
US7294695B2
(en)
|
2000-01-20 |
2007-11-13 |
Genentech, Inc. |
PRO10268 polypeptides
|
WO2001053463A2
(en)
|
2000-01-21 |
2001-07-26 |
Corixa Corporation |
COMPOUNDS AND METHODS FOR PREVENTION AND TREATMENT OF HER-2/neu ASSOCIATED MALIGNANCIES
|
US20030224379A1
(en)
|
2000-01-21 |
2003-12-04 |
Tang Y. Tom |
Novel nucleic acids and polypeptides
|
AU2001238596A1
(en)
|
2000-02-22 |
2001-09-03 |
Millennium Pharmaceuticals, Inc. |
18607, a novel human calcium channel
|
US20030219806A1
(en)
|
2000-02-22 |
2003-11-27 |
Millennium Pharmaceuticals, Inc. |
Novel 18607, 15603, 69318, 12303, 48000, 52920, 5433, 38554, 57301, 58324, 55063, 52991, 59914, 59921 and 33751 molecules and uses therefor
|
US20040002068A1
(en)
|
2000-03-01 |
2004-01-01 |
Corixa Corporation |
Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
|
US20040005561A1
(en)
|
2000-03-01 |
2004-01-08 |
Corixa Corporation |
Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
|
WO2001066689A2
(en)
|
2000-03-07 |
2001-09-13 |
Hyseq, Inc. |
Novel nucleic acids and polypeptides
|
WO2001072962A2
(en)
|
2000-03-24 |
2001-10-04 |
Fahri Saatcioglu |
Novel prostate-specific or testis-specific nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods
|
US20030186889A1
(en)
|
2000-03-31 |
2003-10-02 |
Wolf-Georg Forssmann |
Diagnostic and medicament for analysing the cell surface proteome of tumour and inflammatory cells and for treating tumorous and inflammatory diseases, preferably using a specific chemokine receptor analysis and the chemokine receptor-ligand interaction
|
AU2001253140A1
(en)
|
2000-04-03 |
2001-10-15 |
The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services |
Tumor markers in ovarian cancer
|
US6806054B2
(en)
|
2000-04-07 |
2004-10-19 |
Arena Pharmaceuticals, Inc. |
Non-endogenous, constitutively activated known G protein-coupled receptors
|
CN101289511A
(zh)
|
2000-04-11 |
2008-10-22 |
杰南技术公司 |
多价抗体及其应用
|
US20030119115A1
(en)
|
2000-05-17 |
2003-06-26 |
Genentech, Inc. |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
WO2001090304A2
(en)
|
2000-05-19 |
2001-11-29 |
Human Genome Sciences, Inc. |
Nucleic acids, proteins, and antibodies
|
US20020051990A1
(en)
|
2000-06-09 |
2002-05-02 |
Eric Ople |
Novel gene targets and ligands that bind thereto for treatment and diagnosis of ovarian carcinomas
|
JP2004523203A
(ja)
|
2000-06-16 |
2004-08-05 |
インサイト・ゲノミックス・インコーポレイテッド |
Gタンパク質結合受容体
|
EP1383892A2
(en)
|
2000-06-30 |
2004-01-28 |
Incyte Genomics, Inc. |
Human extracellular matrix and cell adhesion polypeptides
|
EP1294885A2
(en)
|
2000-06-30 |
2003-03-26 |
Amgen, Inc. |
B7-like molecules and uses thereof
|
EP1301524A1
(en)
|
2000-06-30 |
2003-04-16 |
Human Genome Sciences, Inc. |
B7-like polynucleotides, polypeptides, and antibodies
|
AU2002214531A1
(en)
|
2000-07-03 |
2002-01-30 |
Curagen Corporation |
Proteins and nucleic acids encoding same
|
US20040044179A1
(en)
|
2000-07-25 |
2004-03-04 |
Genentech, Inc. |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
WO2002010187A1
(en)
|
2000-07-27 |
2002-02-07 |
Mayo Foundation For Medical Education And Research |
B7-h3 and b7-h4, novel immunoregulatory molecules
|
DE60134178D1
(de)
|
2000-07-28 |
2008-07-03 |
Ulrich Wissenbach |
Trp8 krebsmarker
|
US7229623B1
(en)
|
2000-08-03 |
2007-06-12 |
Corixa Corporation |
Her-2/neu fusion proteins
|
WO2002013847A2
(en)
|
2000-08-14 |
2002-02-21 |
Corixa Corporation |
Methods for diagnosis and therapy of hematological and virus-associated malignancies
|
WO2002014503A2
(en)
|
2000-08-14 |
2002-02-21 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of her-2/neu-associated malignancies
|
EP1445317A3
(en)
|
2000-08-24 |
2004-12-15 |
Genentech Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
GB0020953D0
(en)
|
2000-08-24 |
2000-10-11 |
Smithkline Beecham Biolog |
Vaccine
|
US7208157B2
(en)
|
2000-09-08 |
2007-04-24 |
California Institute Of Technology |
Proteolysis targeting chimeric pharmaceutical
|
EP1346040A2
(en)
|
2000-09-11 |
2003-09-24 |
Nuvelo, Inc. |
Novel nucleic acids and polypeptides
|
US6613567B1
(en)
|
2000-09-15 |
2003-09-02 |
Isis Pharmaceuticals, Inc. |
Antisense inhibition of Her-2 expression
|
US20060073551A1
(en)
|
2000-09-15 |
2006-04-06 |
Genentech, Inc. |
Pro4487 polypeptides
|
DE60121808T2
(de)
|
2000-09-15 |
2007-03-29 |
Zymogenetics, Inc., Seattle |
Verwendung eines polypeptids, welches die extrazelluläre domäne von il-20ra und il-20rb enthält, zur behandlung von entzündungen
|
AU9272401A
(en)
|
2000-09-18 |
2002-03-26 |
Biogen Inc |
Cripto mutant and uses thereof
|
UA83458C2
(uk)
|
2000-09-18 |
2008-07-25 |
Байоджен Айдек Ма Інк. |
Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
|
US7064191B2
(en)
|
2000-10-06 |
2006-06-20 |
Kyowa Hakko Kogyo Co., Ltd. |
Process for purifying antibody
|
US6946292B2
(en)
|
2000-10-06 |
2005-09-20 |
Kyowa Hakko Kogyo Co., Ltd. |
Cells producing antibody compositions with increased antibody dependent cytotoxic activity
|
PL218428B1
(pl)
|
2000-10-06 |
2014-12-31 |
Kyowa Hakko Kogyo Kk |
Komórka, sposoby wytwarzania przeciwciał, leki zawierające przeciwciała, komórka CHO i przeciwciało klasy IgG
|
EP1474528A4
(en)
|
2000-10-13 |
2006-06-14 |
Protein Design Labs Inc |
METHODS FOR DIAGNOSING PROSTATE CANCER, COMPOSITIONS AND METHODS FOR SCREENING PROSTATE CANCER MODULATORS
|
US6596541B2
(en)
|
2000-10-31 |
2003-07-22 |
Regeneron Pharmaceuticals, Inc. |
Methods of modifying eukaryotic cells
|
AU2002230659A1
(en)
|
2000-11-07 |
2002-05-21 |
Zymogenetics Inc. |
Human tumor necrosis factor receptor
|
US20020150573A1
(en)
|
2000-11-10 |
2002-10-17 |
The Rockefeller University |
Anti-Igalpha-Igbeta antibody for lymphoma therapy
|
DE60131456T2
(de)
|
2000-11-30 |
2008-07-10 |
Medarex, Inc., Milpitas |
Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern
|
WO2002061087A2
(en)
|
2000-12-19 |
2002-08-08 |
Lifespan Biosciences, Inc. |
Antigenic peptides, such as for g protein-coupled receptors (gpcrs), antibodies thereto, and systems for identifying such antigenic peptides
|
WO2002054940A2
(en)
|
2001-01-12 |
2002-07-18 |
University Of Medicine & Dentistry Of New Jersey |
Bone morphogenetic protein-2 in the treatment and diagnosis of cancer
|
US20030119133A1
(en)
|
2001-01-16 |
2003-06-26 |
Genentech, Inc. |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
US20030119125A1
(en)
|
2001-01-16 |
2003-06-26 |
Genentech, Inc. |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
US7754208B2
(en)
|
2001-01-17 |
2010-07-13 |
Trubion Pharmaceuticals, Inc. |
Binding domain-immunoglobulin fusion proteins
|
JP2005503760A
(ja)
|
2001-01-24 |
2005-02-10 |
プロテイン デザイン ラブス, インコーポレイテッド |
乳癌の診断方法、組成物および乳癌のモジュレーターのスクリーニング方法
|
US20030073144A1
(en)
|
2001-01-30 |
2003-04-17 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of pancreatic cancer
|
US20040170994A1
(en)
|
2001-02-12 |
2004-09-02 |
Callen David Frederick |
DNA sequences for human tumour suppressor genes
|
AU2002258518A1
(en)
|
2001-03-14 |
2002-09-24 |
Millennium Pharmaceuticals, Inc. |
Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer
|
WO2002078524A2
(en)
|
2001-03-28 |
2002-10-10 |
Zycos Inc. |
Translational profiling
|
WO2003008537A2
(en)
|
2001-04-06 |
2003-01-30 |
Mannkind Corporation |
Epitope sequences
|
US6820011B2
(en)
|
2001-04-11 |
2004-11-16 |
The Regents Of The University Of Colorado |
Three-dimensional structure of complement receptor type 2 and uses thereof
|
EP1414477B1
(en)
|
2001-04-17 |
2015-06-10 |
The Board Of Trustees Of The University Of Arkansas |
Repeat sequences of the ca125 gene and their use for diagnostic interventions
|
EP1463928A2
(en)
|
2001-04-18 |
2004-10-06 |
Protein Design Labs |
Methods of diagnosis of lung cancer, compositions and methods of screening for modulators of lung cancer
|
WO2003083041A2
(en)
|
2002-03-22 |
2003-10-09 |
Biogen, Inc. |
Cripto-specific antibodies
|
CN100352501C
(zh)
|
2001-04-26 |
2007-12-05 |
比奥根艾迪克Ma公司 |
Cripto阻断抗体及其用途
|
JP2005504513A
(ja)
|
2001-05-09 |
2005-02-17 |
コリクサ コーポレイション |
前立腺癌の治療及び診断のための組成物及び方法
|
AU2002344326A1
(en)
|
2001-05-11 |
2002-11-25 |
Sloan-Kettering Institute For Cancer Research |
Nucleic acid sequence encoding ovarian antigen, ca125, and uses thereof
|
DE60234202D1
(de)
|
2001-05-24 |
2009-12-10 |
Zymogenetics Inc |
Taci-immunoglobulin-fusionsproteine
|
US7157558B2
(en)
|
2001-06-01 |
2007-01-02 |
Genentech, Inc. |
Polypeptide encoded by a polynucleotide overexpresses in tumors
|
WO2002098358A2
(en)
|
2001-06-04 |
2002-12-12 |
Eos Biotechnology, Inc. |
Methods of diagnosis and treatment of androgen-dependent prostate cancer, prostate cancer undergoing androgen-withdrawal, and androgen-independent prostate cancer
|
WO2003000842A2
(en)
|
2001-06-04 |
2003-01-03 |
Curagen Corporation |
Novel proteins and nucleic acids encoding same
|
WO2002099140A1
(en)
|
2001-06-05 |
2002-12-12 |
Exelixis, Inc. |
GLRAs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
|
US20050170344A1
(en)
|
2001-06-05 |
2005-08-04 |
Lori Friedman |
Chds as modifiers of the p53 pathway and methods of use
|
US7235358B2
(en)
|
2001-06-08 |
2007-06-26 |
Expression Diagnostics, Inc. |
Methods and compositions for diagnosing and monitoring transplant rejection
|
WO2002101075A2
(en)
|
2001-06-13 |
2002-12-19 |
Millennium Pharmaceuticals, Inc. |
Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer
|
AU2002347428A1
(en)
|
2001-06-18 |
2003-01-02 |
Eos Biotechnology Inc. |
Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
|
US7189507B2
(en)
|
2001-06-18 |
2007-03-13 |
Pdl Biopharma, Inc. |
Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
|
AU2002322280A1
(en)
|
2001-06-21 |
2003-01-21 |
Millennium Pharmaceuticals, Inc. |
Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
|
US20030108958A1
(en)
|
2001-06-28 |
2003-06-12 |
Rene De Waal Malefyt |
Biological activity of AK155
|
AU2002314433A1
(en)
|
2001-07-02 |
2003-01-21 |
Licentia Ltd. |
Ephrin-tie receptor materials and methods
|
US20040076955A1
(en)
|
2001-07-03 |
2004-04-22 |
Eos Biotechnology, Inc. |
Methods of diagnosis of bladder cancer, compositions and methods of screening for modulators of bladder cancer
|
WO2003003984A2
(en)
|
2001-07-05 |
2003-01-16 |
Curagen Corporation |
Novel proteins and nucleic acids encoding same
|
US7446185B2
(en)
|
2001-07-18 |
2008-11-04 |
The Regents Of The University Of California |
Her2/neu target antigen and use of same to stimulate an immune response
|
US20030108963A1
(en)
|
2001-07-25 |
2003-06-12 |
Millennium Pharmaceuticals, Inc. |
Novel genes, compositions, kit, and methods for identification, assessment, prevention and therapy of prostate cancer
|
KR20100018071A
(ko)
|
2001-08-03 |
2010-02-16 |
글리카트 바이오테크놀로지 아게 |
항체 의존적 세포 독성이 증가된 항체 글리코실화 변이체
|
IL160127A0
(en)
|
2001-08-03 |
2004-06-20 |
Genentech Inc |
Tacis and br3 polypeptides and uses thereof
|
US20070015145A1
(en)
|
2001-08-14 |
2007-01-18 |
Clifford Woolf |
Nucleic acid and amino acid sequences involved in pain
|
US20030092013A1
(en)
|
2001-08-16 |
2003-05-15 |
Vitivity, Inc. |
Diagnosis and treatment of vascular disease
|
WO2003018621A2
(en)
|
2001-08-23 |
2003-03-06 |
Oxford Biomedica (Uk) Limited |
Genes
|
AU2002357643A1
(en)
|
2001-08-29 |
2003-04-14 |
Vanderbilt University |
The human mob-5 (il-24) receptors and uses thereof
|
US20030124579A1
(en)
|
2001-09-05 |
2003-07-03 |
Eos Biotechnology, Inc. |
Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
|
EP2287186B1
(en)
|
2001-09-06 |
2014-12-31 |
Agensys, Inc. |
Nucleic acid and corresponding protein entitled STEAP-1 useful in treatment and detection of cancer
|
WO2003025138A2
(en)
|
2001-09-17 |
2003-03-27 |
Protein Design Labs, Inc. |
Methods of diagnosis of cancer compositions and methods of screening for modulators of cancer
|
US20050004017A1
(en)
|
2001-09-18 |
2005-01-06 |
Yuval Reiss |
Methods and compositions for treating hcap associated diseases
|
NZ573831A
(en)
|
2001-09-18 |
2010-07-30 |
Genentech Inc |
Compositions and methods for the diagnosis and treatment of tumor, particularly breast tumor - TAT193
|
CA2460621A1
(en)
|
2001-09-19 |
2003-03-27 |
Nuvelo, Inc. |
Novel nucleic acids and polypeptides
|
US20030077644A1
(en)
|
2001-09-28 |
2003-04-24 |
Bing Yang |
Diagnosis and treatment of diseases caused by mutations in CD72
|
AU2002362454A1
(en)
|
2001-10-03 |
2003-04-14 |
Origene Technologies, Inc. |
Regulated breast cancer genes
|
WO2003029277A2
(en)
|
2001-10-03 |
2003-04-10 |
Rigel Pharmaceuticals, Inc. |
Modulators of lymphocyte activation and migration
|
CA2461665A1
(en)
|
2001-10-19 |
2003-05-01 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of inflammatory bowel disorders
|
US20040241703A1
(en)
|
2002-08-19 |
2004-12-02 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
US20050123925A1
(en)
|
2002-11-15 |
2005-06-09 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
WO2003035846A2
(en)
|
2001-10-24 |
2003-05-01 |
National Jewish Medical And Research Center |
Structure of tall-1 and its cognate receptor
|
KR100988949B1
(ko)
|
2001-10-25 |
2010-10-20 |
제넨테크, 인크. |
당단백질 조성물
|
KR20110032003A
(ko)
|
2001-10-31 |
2011-03-29 |
알콘, 인코퍼레이티드 |
뼈 형태발생 단백질(bmp), bmp 수용체 및 bmp 결합 단백질 및 녹내장 진단 및 치료에서 그의 용도
|
US20030232350A1
(en)
|
2001-11-13 |
2003-12-18 |
Eos Biotechnology, Inc. |
Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
|
WO2003042661A2
(en)
|
2001-11-13 |
2003-05-22 |
Protein Design Labs, Inc. |
Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
|
EP1448226A1
(en)
|
2001-11-29 |
2004-08-25 |
Genset S.A. |
Agonists and antagonists of prolixin for the treatment of metabolic disorders
|
WO2003048202A2
(en)
|
2001-12-03 |
2003-06-12 |
Asahi Kasei Pharma Corporation |
Nf-kappab activating genes
|
AU2002366951A1
(en)
|
2001-12-10 |
2003-07-09 |
Nuvelo,Inc. |
Novel nucleic acids and polypeptides
|
ES2307822T3
(es)
|
2001-12-18 |
2008-12-01 |
F. Hoffmann-La Roche Ag |
Cis-imidazolinas como inhibidores de mdm2.
|
PL370823A1
(pl)
|
2001-12-18 |
2005-05-30 |
F.Hoffmann-La Roche Ag |
Cis-2,4,5-trifenyloimidazoliny i ich zastosowaniew leczeniu nowotworów
|
US20040093621A1
(en)
|
2001-12-25 |
2004-05-13 |
Kyowa Hakko Kogyo Co., Ltd |
Antibody composition which specifically binds to CD20
|
US20030134790A1
(en)
|
2002-01-11 |
2003-07-17 |
University Of Medicine And Dentistry Of New Jersey |
Bone Morphogenetic Protein-2 And Bone Morphogenetic Protein-4 In The Treatment And Diagnosis Of Cancer
|
US7452675B2
(en)
|
2002-01-25 |
2008-11-18 |
The Queen's Medical Center |
Methods of screening for TRPM4b modulators
|
AU2003224624B2
(en)
|
2002-02-21 |
2008-08-28 |
Duke University |
Reagents and treatment methods for autoimmune diseases
|
JP2005535290A
(ja)
|
2002-02-22 |
2005-11-24 |
ジェネンテック・インコーポレーテッド |
免疫関連疾患の治療のための組成物と方法
|
US20030219795A1
(en)
|
2002-03-01 |
2003-11-27 |
Marcia Belvin |
SCDs as modifiers of the p53 pathway and methods of use
|
WO2003104399A2
(en)
|
2002-06-07 |
2003-12-18 |
Avalon Pharmaceuticals, Inc |
Cancer-linked gene as target for chemotherapy
|
EP2258712A3
(en)
|
2002-03-15 |
2011-05-04 |
Multicell Immunotherapeutics, Inc. |
Compositions and Methods to Initiate or Enhance Antibody and Major-histocompatibility Class I or Class II-restricted T Cell Responses by Using Immunomodulatory, Non-coding RNA Motifs
|
CA2486490A1
(en)
|
2002-03-19 |
2003-12-31 |
Curagen Corporation |
Therapeutic polypeptides, nucleic acids encoding same, and methods of use
|
US7202033B2
(en)
|
2002-03-21 |
2007-04-10 |
Sunesis Pharmaceuticals, Inc. |
Identification of kinase inhibitors
|
US7193069B2
(en)
|
2002-03-22 |
2007-03-20 |
Research Association For Biotechnology |
Full-length cDNA
|
EP1490085A2
(en)
|
2002-03-25 |
2004-12-29 |
Uab Research Foundation |
Fc receptor homolog, reagents, and uses thereof
|
WO2003083074A2
(en)
|
2002-03-28 |
2003-10-09 |
Idec Pharmaceuticals Corporation |
Novel gene targets and ligands that bind thereto for treatment and diagnosis of colon carcinomas
|
US20030194704A1
(en)
|
2002-04-03 |
2003-10-16 |
Penn Sharron Gaynor |
Human genome-derived single exon nucleic acid probes useful for gene expression analysis two
|
MXPA04009728A
(es)
|
2002-04-05 |
2005-06-08 |
Agenysys Inc |
Acido nucleico y proteina correspondiente titulada 98p4b6 en el tratamiento y deteccion del cancer.
|
US20050031613A1
(en)
|
2002-04-09 |
2005-02-10 |
Kazuyasu Nakamura |
Therapeutic agent for patients having human FcgammaRIIIa
|
US7749753B2
(en)
|
2002-04-09 |
2010-07-06 |
Kyowa Hakko Kirin Co., Ltd |
Cells in which activity of the protein involved in transportation of GDP-fucose is reduced or lost
|
JPWO2003084569A1
(ja)
|
2002-04-09 |
2005-08-11 |
協和醗酵工業株式会社 |
抗体組成物含有医薬
|
CA2481657A1
(en)
|
2002-04-09 |
2003-10-16 |
Kyowa Hakko Kogyo Co., Ltd. |
Cells of which genome is modified
|
JPWO2003085118A1
(ja)
|
2002-04-09 |
2005-08-11 |
協和醗酵工業株式会社 |
抗体組成物の製造方法
|
AU2003236018A1
(en)
|
2002-04-09 |
2003-10-20 |
Kyowa Hakko Kirin Co., Ltd. |
METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcGamma RECEPTOR IIIa
|
US20040101874A1
(en)
|
2002-04-12 |
2004-05-27 |
Mitokor Inc. |
Targets for therapeutic intervention identified in the mitochondrial proteome
|
NZ535925A
(en)
|
2002-04-16 |
2008-06-30 |
Genentech Inc |
An isolated antibody that binds to a particular polypeptide
|
WO2003089904A2
(en)
|
2002-04-17 |
2003-10-30 |
Baylor College Of Medicine |
Aib1 as a prognostic marker and predictor of resistance to encocrine therapy
|
WO2003093444A2
(en)
|
2002-05-03 |
2003-11-13 |
Incyte Corporation |
Transporters and ion channels
|
CA2485983A1
(en)
|
2002-05-15 |
2003-11-27 |
Avalon Pharmaceuticals |
Cancer-linked gene as target for chemotherapy
|
US20030224454A1
(en)
|
2002-05-30 |
2003-12-04 |
Ryseck Rolf Peter |
Human solute carrier family 7, member 11 (hSLC7A11)
|
NZ556507A
(en)
|
2002-06-03 |
2010-03-26 |
Genentech Inc |
Synthetic antibody phage libraries
|
WO2003101283A2
(en)
|
2002-06-04 |
2003-12-11 |
Incyte Corporation |
Diagnostics markers for lung cancer
|
CA2488284A1
(en)
|
2002-06-04 |
2003-12-11 |
Avalon Pharmaceuticals, Inc. |
Cancer-linked gene as target for chemotherapy
|
DE60336227D1
(de)
|
2002-06-06 |
2011-04-14 |
Oncotherapy Science Inc |
Gene und proteine mit bezug zu menschlichem kolonkrebs
|
AU2003242633A1
(en)
|
2002-06-06 |
2003-12-22 |
Molecular Engines Laboratories |
Dudulin genes, non-human animal model: uses in human hematological disease
|
AU2003245441A1
(en)
|
2002-06-12 |
2003-12-31 |
Avalon Pharmaceuticals, Inc. |
Cancer-linked gene as target for chemotherapy
|
US20040249130A1
(en)
|
2002-06-18 |
2004-12-09 |
Martin Stanton |
Aptamer-toxin molecules and methods for using same
|
JP2005533794A
(ja)
|
2002-06-18 |
2005-11-10 |
アーケミックス コーポレイション |
アプタマー−毒素分子およびこれを使用する方法
|
AU2003245615A1
(en)
|
2002-06-20 |
2004-01-06 |
The Regents Of The University Of California |
Compositions and methods for modulating lymphocyte activity
|
EP2365004B1
(en)
|
2002-06-21 |
2016-01-06 |
Johns Hopkins University School of Medicine |
Membrane associated tumor endothelium markers
|
AU2003281515A1
(en)
|
2002-07-19 |
2004-02-09 |
Cellzome Ag |
Protein complexes of cellular networks underlying the development of cancer and other diseases
|
JP2005533863A
(ja)
|
2002-07-25 |
2005-11-10 |
ジェネンテック・インコーポレーテッド |
Taci抗体とその用途
|
AU2003251471A1
(en)
|
2002-08-06 |
2004-02-25 |
Bayer Healthcare Ag |
Diagnostics and therapeutics for diseases associated with human cxc chemokine receptor 5(cxcr5)
|
JP2004121218A
(ja)
|
2002-08-06 |
2004-04-22 |
Jenokkusu Soyaku Kenkyusho:Kk |
気管支喘息または慢性閉塞性肺疾患の検査方法
|
JP2006515742A
(ja)
|
2002-08-27 |
2006-06-08 |
ブリストル−マイヤーズ スクイブ カンパニー |
乳癌細胞でのプロテインチロシンキナーゼおよび/またはプロテインチロシンキナーゼ経路と相互作用および/またはモデュレートする化合物の活性を予測するためのポリヌクレオチドの同定
|
WO2004020595A2
(en)
|
2002-08-29 |
2004-03-11 |
Five Prime Therapeutics, Inc. |
Novel human polypeptides encoded by polynucleotides
|
AU2002951346A0
(en)
|
2002-09-05 |
2002-09-26 |
Garvan Institute Of Medical Research |
Diagnosis of ovarian cancer
|
WO2004022709A2
(en)
|
2002-09-06 |
2004-03-18 |
Mannkind Corporation |
Epitope sequences
|
EP1581648A2
(en)
|
2002-09-09 |
2005-10-05 |
Nura, Inc. |
G protein coupled receptors and uses thereof
|
JP2004113151A
(ja)
|
2002-09-27 |
2004-04-15 |
Sankyo Co Ltd |
癌遺伝子及びその用途
|
CA2500978A1
(en)
|
2002-10-03 |
2004-04-15 |
Mcgill University |
Antibodies and cyclic peptides which bind cea (carcinoembryonic antigen) and their use as cancer therapeutics
|
CA2501131A1
(en)
|
2002-10-04 |
2004-04-22 |
Van Andel Research Institute |
Molecular sub-classification of kidney tumors and the discovery of new diagnostic markers
|
US7361740B2
(en)
|
2002-10-15 |
2008-04-22 |
Pdl Biopharma, Inc. |
Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
|
EP1578447A4
(en)
|
2002-10-31 |
2009-06-03 |
Genentech Inc |
METHODS AND COMPOSITIONS THAT CAN INCREASE ANTIBODY PRODUCTION
|
AU2003295401B2
(en)
|
2002-11-08 |
2010-04-29 |
Genentech, Inc. |
Compositions and methods for the treatment of natural killer cell related diseases
|
WO2004044178A2
(en)
|
2002-11-13 |
2004-05-27 |
Genentech, Inc. |
Methods and compositions for diagnosing dysplasia
|
EP1578372A4
(en)
|
2002-11-15 |
2007-10-17 |
Univ Arkansas |
CA125 GENE AND ITS USE IN DIAGNOSTIC AND THERAPEUTIC INTERVENTIONS
|
US8007804B2
(en)
|
2002-11-15 |
2011-08-30 |
Musc Foundation For Research Development |
Complement receptor 2 targeted complement modulators
|
AU2003297300A1
(en)
|
2002-11-20 |
2004-06-15 |
Biogen Idec Inc. |
Novel gene targets and ligands that bind thereto for treatment and diagnosis of carcinomas
|
WO2004047749A2
(en)
|
2002-11-21 |
2004-06-10 |
University Of Utah Research Foundation |
Purinergic modulation of smell
|
AU2003298786A1
(en)
|
2002-11-26 |
2004-06-18 |
Protein Design Labs, Inc. |
Methods of detecting soft tissue sarcoma, compositions and methods of screening for soft tissue sarcoma modulators
|
AU2003302774A1
(en)
|
2002-12-06 |
2004-06-30 |
Diadexus, Inc. |
Compositions, splice variants and methods relating to ovarian specific genes and proteins
|
US20040157278A1
(en)
|
2002-12-13 |
2004-08-12 |
Bayer Corporation |
Detection methods using TIMP 1
|
ES2347241T3
(es)
|
2002-12-16 |
2010-10-27 |
Genentech, Inc. |
Variantes de inmunoglobulina y sus utilizaciones.
|
WO2004058171A2
(en)
|
2002-12-20 |
2004-07-15 |
Protein Design Labs, Inc. |
Antibodies against gpr64 and uses thereof
|
US20050249671A9
(en)
|
2002-12-23 |
2005-11-10 |
David Parmelee |
Neutrokine-alpha conjugate, neutrokine-alpha complex, and uses thereof
|
CA2512536A1
(en)
|
2003-01-08 |
2004-07-29 |
Bristol-Myers Squibb Company |
Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators
|
WO2004063355A2
(en)
|
2003-01-10 |
2004-07-29 |
Protein Design Labs, Inc. |
Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of matastatic cancer
|
US20050227301A1
(en)
|
2003-01-10 |
2005-10-13 |
Polgen |
Cell cycle progression proteins
|
US20040171823A1
(en)
|
2003-01-14 |
2004-09-02 |
Nadler Steven G. |
Polynucleotides and polypeptides associated with the NF-kappaB pathway
|
US7258971B2
(en)
|
2003-01-15 |
2007-08-21 |
Bayer Healthcare Ag |
Methods and compositions for treating urological disorders using carboxypeptidase Z identified as 8263
|
AU2004205631A1
(en)
|
2003-01-16 |
2004-08-05 |
Genentech, Inc. |
Synthetic antibody phage libraries
|
EP1585768A2
(en)
|
2003-01-23 |
2005-10-19 |
Genentech, Inc. |
Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
|
EP1594893A2
(en)
|
2003-02-14 |
2005-11-16 |
Sagres Discovery, Inc. |
Therapeutic targets in cancer
|
US6916833B2
(en)
|
2003-03-13 |
2005-07-12 |
Hoffmann-La Roche Inc. |
Substituted piperidines
|
US20030224411A1
(en)
|
2003-03-13 |
2003-12-04 |
Stanton Lawrence W. |
Genes that are up- or down-regulated during differentiation of human embryonic stem cells
|
CA2528119A1
(en)
|
2003-06-17 |
2005-01-13 |
F. Hoffmann-La Roche Ag |
Cis-2,4,5-triaryl-imidazolines
|
CA2528096C
(en)
|
2003-06-17 |
2011-09-13 |
F. Hoffmann-La Roche Ag |
Cis-imidazolines as mdm2 inhibitors
|
EP1688439A4
(en)
|
2003-10-08 |
2007-12-19 |
Kyowa Hakko Kogyo Kk |
HYBRID PROTEIN COMPOSITION
|
AU2004280065A1
(en)
|
2003-10-09 |
2005-04-21 |
Kyowa Hakko Kirin Co., Ltd. |
Process for producing antibody composition by using RNA inhibiting the function of alpha1,6-fucosyltransferase
|
US9296820B2
(en)
|
2003-11-05 |
2016-03-29 |
Roche Glycart Ag |
Polynucleotides encoding anti-CD20 antigen binding molecules with increased Fc receptor binding affinity and effector function
|
ES2697327T3
(es)
|
2003-11-06 |
2019-01-23 |
Seattle Genetics Inc |
Compuesto intermedio para la preparación de conjugados que comprenden derivados de auristatina y un enlazador
|
WO2005053742A1
(ja)
|
2003-12-04 |
2005-06-16 |
Kyowa Hakko Kogyo Co., Ltd. |
抗体組成物を含有する医薬
|
CN1961003B
(zh)
|
2004-03-31 |
2013-03-27 |
健泰科生物技术公司 |
人源化抗TGF-β抗体
|
US7785903B2
(en)
|
2004-04-09 |
2010-08-31 |
Genentech, Inc. |
Variable domain library and uses
|
SG172616A1
(en)
|
2004-04-13 |
2011-07-28 |
Hoffmann La Roche |
Anti-p-selectin antibodies
|
KR100832277B1
(ko)
|
2004-05-18 |
2008-05-26 |
에프. 호프만-라 로슈 아게 |
신규 cis-이미다졸린
|
US7893278B2
(en)
|
2004-06-17 |
2011-02-22 |
Hoffman-La Roche Inc. |
CIS-imidazolines
|
TWI380996B
(zh)
|
2004-09-17 |
2013-01-01 |
Hoffmann La Roche |
抗ox40l抗體
|
WO2006032631A1
(en)
|
2004-09-22 |
2006-03-30 |
Janssen Pharmaceutica N.V. |
Inhibitors of the interaction between mdm2 and p53
|
JP4948413B2
(ja)
|
2004-09-23 |
2012-06-06 |
ジェネンテック, インコーポレイテッド |
システイン操作抗体および結合体
|
CA2598690C
(en)
|
2005-02-22 |
2011-11-15 |
The Regents Of The University Of Michigan |
Small molecule inhibitors of mdm2 and uses thereof
|
US7579368B2
(en)
|
2005-03-16 |
2009-08-25 |
Hoffman-La Roche Inc. |
Cis-imidazolines
|
JP5196654B2
(ja)
|
2005-06-20 |
2013-05-15 |
ジェネンテック, インコーポレイテッド |
腫瘍の診断と治療のための組成物と方法
|
US7576082B2
(en)
|
2005-06-24 |
2009-08-18 |
Hoffman-La Roche Inc. |
Oxindole derivatives
|
EP2465870A1
(en)
|
2005-11-07 |
2012-06-20 |
Genentech, Inc. |
Binding polypeptides with diversified and consensus VH/VL hypervariable sequences
|
NZ568285A
(en)
|
2005-12-01 |
2011-08-26 |
Hoffmann La Roche |
2,4,5-triphenyl imidazoline derivatives as inhibitors of the interaction between P53 and MDM2 proteins for use as anticancer agents
|
EP1973951A2
(en)
|
2005-12-02 |
2008-10-01 |
Genentech, Inc. |
Binding polypeptides with restricted diversity sequences
|
WO2007082805A1
(en)
|
2006-01-18 |
2007-07-26 |
F. Hoffmann-La Roche Ag |
Cis-4, 5-biaryl-2-heterocyclic-imidazolines as mdm2 inhibitors
|
US20070213341A1
(en)
|
2006-03-13 |
2007-09-13 |
Li Chen |
Spiroindolinone derivatives
|
WO2007104714A1
(en)
|
2006-03-13 |
2007-09-20 |
F. Hoffmann-La Roche Ag |
Spiroindolinone derivatives
|
JP5162574B2
(ja)
|
2006-03-22 |
2013-03-13 |
ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ |
Mdm2及びp53間の相互作用のインヒビターとしての環式アルキルアミン誘導体
|
CA2644643C
(en)
|
2006-03-22 |
2015-05-19 |
Janssen Pharmaceutica N.V. |
Inhibitors of the interaction between mdm2 and p53
|
EP2016101A2
(en)
|
2006-05-09 |
2009-01-21 |
Genentech, Inc. |
Binding polypeptides with optimized scaffolds
|
US8524865B2
(en)
|
2006-05-30 |
2013-09-03 |
Genentech, Inc. |
Antibodies and immunoconjugates and uses therefor
|
JP2009541275A
(ja)
|
2006-06-22 |
2009-11-26 |
ノボ・ノルデイスク・エー/エス |
二重特異性抗体の生産
|
AU2007297823B2
(en)
|
2006-08-30 |
2012-04-19 |
The Regents Of The University Of Michigan |
New small molecule inhibitors of MDM2 and the uses thereof
|
DK2059533T3
(da)
|
2006-08-30 |
2013-02-25 |
Genentech Inc |
Multispecifikke antistoffer
|
KR101109438B1
(ko)
|
2006-09-21 |
2012-07-12 |
에프. 호프만-라 로슈 아게 |
항암제로서의 옥신돌 유도체
|
US7638548B2
(en)
|
2006-11-09 |
2009-12-29 |
Hoffmann-La Roche Inc. |
Spiroindolinone derivatives
|
JPWO2008072655A1
(ja)
|
2006-12-14 |
2010-04-02 |
第一三共株式会社 |
イミダゾチアゾール誘導体
|
US20080226635A1
(en)
|
2006-12-22 |
2008-09-18 |
Hans Koll |
Antibodies against insulin-like growth factor I receptor and uses thereof
|
WO2008106507A2
(en)
|
2007-02-27 |
2008-09-04 |
University Of South Florida |
Mdm2/mdmx inhibitor peptide
|
US7625895B2
(en)
|
2007-04-12 |
2009-12-01 |
Hoffmann-Le Roche Inc. |
Diphenyl-dihydro-imidazopyridinones
|
WO2008130614A2
(en)
|
2007-04-20 |
2008-10-30 |
University Of Pittsburg-Of The Commonwealth System Of Higher Education |
Selective and dual-action p53/mdm2/mdm4 antagonists
|
CL2008001334A1
(es)
|
2007-05-08 |
2008-09-22 |
Genentech Inc |
Anticuerpo anti-muc16 disenado con cisteina; conjugado que lo comprende; metodo de produccion; formulacion farmaceutica que lo comprende; y su uso para tratar el cancer.
|
US7553833B2
(en)
|
2007-05-17 |
2009-06-30 |
Hoffmann-La Roche Inc. |
3,3-spiroindolinone derivatives
|
US7834179B2
(en)
|
2007-05-23 |
2010-11-16 |
Hoffmann-La Roche Inc. |
Spiroindolinone derivatives
|
CN100592373C
(zh)
|
2007-05-25 |
2010-02-24 |
群康科技(深圳)有限公司 |
液晶显示面板驱动装置及其驱动方法
|
ES2534899T3
(es)
|
2007-08-06 |
2015-04-30 |
Janssen Pharmaceutica, N.V. |
Fenilendiaminas sustituidas como inhibidores de la interacción entre MDM2 y p53
|
US8288377B2
(en)
|
2007-09-21 |
2012-10-16 |
Janssen Pharmaceutica N.V. |
Inhibitors of the interaction between MDM2 and p53
|
JO2704B1
(en)
|
2007-09-21 |
2013-03-03 |
جانسين فارماسوتيكا ان في |
Interference inhibition factors between MD2 and B53
|
AU2008309759A1
(en)
|
2007-10-09 |
2009-04-16 |
F. Hoffmann-La Roche Ag |
Chiral CIS-imidazolines
|
CN101835803B
(zh)
|
2007-10-19 |
2016-05-25 |
健泰科生物技术公司 |
半胱氨酸改造的抗tenb2抗体和抗体药物偶联物
|
US8134001B2
(en)
|
2007-12-14 |
2012-03-13 |
Hoffmann-La Roche Inc. |
Spiroindolinone derivatives
|
US7776875B2
(en)
|
2007-12-19 |
2010-08-17 |
Hoffman-La Roche Inc. |
Spiroindolinone derivatives
|
DK2235064T3
(en)
|
2008-01-07 |
2016-01-11 |
Amgen Inc |
A process for the preparation of heterodimeric Fc molecules using electrostatic control effects
|
US7723372B2
(en)
|
2008-03-19 |
2010-05-25 |
Hoffman-La Roche Inc. |
Spiroindolinone derivatives
|
WO2009151069A1
(ja)
|
2008-06-12 |
2009-12-17 |
第一三共株式会社 |
4,7-ジアザスピロ[2.5]オクタン環構造を有するイミダゾチアゾール誘導体
|
BRPI0910810A2
(pt)
|
2008-07-15 |
2019-09-24 |
Genentech Inc |
conjugados derivados de antraciclina, veículo polimérico, anticorpo, peptídeo ou proteína, veículo t-[cho]m, composições farmacêuticas, métodos de tratamento do câncer ou de distúrbios da proliferação celular, derivado de antraciclina, composto conjugado droga-anticorpo, uso, artigo de manufatura e método de produção de um composto conjugado droga-anticorpo"
|
TW201011009A
(en)
|
2008-09-15 |
2010-03-16 |
Priaxon Ag |
Novel pyrrolidin-2-ones
|
US8354444B2
(en)
|
2008-09-18 |
2013-01-15 |
Hoffmann-La Roche Inc. |
Substituted pyrrolidine-2-carboxamides
|
JP2010120881A
(ja)
|
2008-11-19 |
2010-06-03 |
Keio Gijuku |
ヒト癌タンパク質MDM2とヒト癌抑制タンパク質p53との相互作用阻害ペプチド及びその使用
|
ES2463820T3
(es)
|
2009-01-16 |
2014-05-29 |
Daiichi Sankyo Company, Limited |
Derivado de imidazotiazol que tiene estructura de anillo de prolina
|
US20100190814A1
(en)
|
2009-01-26 |
2010-07-29 |
Li Chen |
Spiroindolinone derivative prodrugs
|
US7928233B2
(en)
|
2009-02-10 |
2011-04-19 |
Hoffmann-La Roche Inc. |
Spiroindolinone pyridine derivatives
|
US8217051B2
(en)
|
2009-02-17 |
2012-07-10 |
Hoffmann-La Roche Inc. |
Spiroindolinone derivatives
|
US8076482B2
(en)
|
2009-04-23 |
2011-12-13 |
Hoffmann-La Roche Inc. |
3,3′-spiroindolinone derivatives
|
WO2011005219A1
(en)
|
2009-07-07 |
2011-01-13 |
Agency For Science, Technology And Research |
Novel mdm2 binding peptides and uses thereof
|
US20120149661A1
(en)
|
2009-08-26 |
2012-06-14 |
Novartis Ag |
Tetra-substituted heteroaryl compounds and their use as mdm2 and/or mdm4 modulators
|
US8017607B2
(en)
|
2009-10-14 |
2011-09-13 |
Hoffmann-La Roche Inc. |
N-substituted-pyrrolidines as inhibitors of MDM2-P-53 interactions
|
BR112012011317A2
(pt)
|
2009-11-12 |
2019-09-24 |
Univ Michigan Regents |
antagonistas espiro-oxindóis de mdm2
|
US20110118283A1
(en)
|
2009-11-17 |
2011-05-19 |
Qingjie Ding |
Substituted Pyrrolidine-2-Carboxamides
|
US8088815B2
(en)
|
2009-12-02 |
2012-01-03 |
Hoffman-La Roche Inc. |
Spiroindolinone pyrrolidines
|
US8440693B2
(en)
|
2009-12-22 |
2013-05-14 |
Novartis Ag |
Substituted isoquinolinones and quinazolinones
|
CU24130B1
(es)
|
2009-12-22 |
2015-09-29 |
Novartis Ag |
Isoquinolinonas y quinazolinonas sustituidas
|
EP2516396A1
(en)
|
2009-12-23 |
2012-10-31 |
Wayne State University |
Therapeutic compounds
|
EP2536756B1
(en)
|
2010-02-16 |
2018-04-25 |
MedImmune, LLC |
Hsa-related compositions and methods of use
|
US8288431B2
(en)
|
2010-02-17 |
2012-10-16 |
Hoffmann-La Roche Inc. |
Substituted spiroindolinones
|
WO2011106650A2
(en)
|
2010-02-27 |
2011-09-01 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Education |
Novel p53-mdm2/p53-mdm4 antagonists to treat proliferative disease
|
CN102947335B
(zh)
*
|
2010-04-15 |
2018-11-06 |
基因泰克公司 |
抗多聚遍在蛋白抗体及使用方法
|
CA2796633C
(en)
|
2010-04-23 |
2020-10-27 |
Genentech, Inc. |
Production of heteromultimeric proteins
|
US8217044B2
(en)
|
2010-04-28 |
2012-07-10 |
Hoffmann-La Roche Inc. |
Spiroindolinone pyrrolidines
|
JO2998B1
(ar)
|
2010-06-04 |
2016-09-05 |
Amgen Inc |
مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان
|
US20120010235A1
(en)
|
2010-07-12 |
2012-01-12 |
Xin-Jie Chu |
N-substituted pyrrolidines
|
US20120046306A1
(en)
|
2010-08-18 |
2012-02-23 |
David Joseph Bartkovitz |
Substituted Heteroaryl Spiropyrrolidine MDM2 Antagonists
|
EP2614051A4
(en)
|
2010-09-08 |
2014-01-29 |
Univ Pittsburgh |
P53-MDM2 ANTAGONISTS
|
US20120065210A1
(en)
|
2010-09-15 |
2012-03-15 |
Xin-Jie Chu |
Substituted hexahydropyrrolo[1,2-c]imidazolones
|
US20120071499A1
(en)
|
2010-09-20 |
2012-03-22 |
Xin-Jie Chu |
Substituted Spiro[3H-Indole-3,6'(5'H)-[1H]Pyrrolo[1,2c]Imidazole-1',2(1H,2'H)-diones
|
US20130225603A1
(en)
|
2010-09-27 |
2013-08-29 |
Serrata Llc |
Mdm2 inhibitors for treatment of ocular conditions
|
MX2013005238A
(es)
|
2010-11-12 |
2013-09-02 |
Univ Michigan |
Antagonistas de mdm2 de espiro-oxindol.
|
WO2012076513A1
(en)
|
2010-12-09 |
2012-06-14 |
F. Hoffmann-La Roche Ag |
3-cyano-1-hydroxymethyl-2-phenylpyrrolidine derivatives as inhibitors of mdm2-p53 interactions useful for the treatment of cancer
|
CA2825064C
(en)
|
2011-02-04 |
2022-08-30 |
Genentech, Inc. |
Fc variants and methods for their production
|
US20130053410A1
(en)
|
2011-03-03 |
2013-02-28 |
David Joseph Bartkovitz |
Substituted heteroaryl 2',3',7',7a'-tetrahydrospiro[pyrrole-3,6'-pyrrolo[1,2-c]imidazole]-1',2(1h,5'h)-dione
|
MY172862A
(en)
|
2011-03-10 |
2019-12-13 |
Daiichi Sankyo Co Ltd |
Dispiropyrrolidine derivatives
|
US9249153B2
(en)
|
2011-03-18 |
2016-02-02 |
Pusan National University Industry-University Cooperation Foundation |
Pharmaceutical composition for treating aging-associated diseases, containing progerin expression inhibitor as active ingredient, and screening method of said progerin expression inhibitor
|
AU2012234335B2
(en)
|
2011-03-29 |
2016-09-01 |
Roche Glycart Ag |
Antibody Fc variants
|
CA2835422C
(en)
|
2011-05-11 |
2016-10-11 |
The Regents Of The University Of Michigan |
Spiro-oxindole mdm2 antagonists
|
US8859586B2
(en)
|
2011-06-20 |
2014-10-14 |
Novartis Ag |
Cyclohexyl isoquinolinone compounds
|
EP2721008B1
(en)
|
2011-06-20 |
2015-04-29 |
Novartis AG |
Hydroxy substituted isoquinolinone derivatives as p53 (mdm2 or mdm4) inhibitors
|
WO2012176123A1
(en)
|
2011-06-22 |
2012-12-27 |
Novartis Ag |
3 - imidazolyl- indoles for the treatment of proliferative diseases
|
WO2013017705A1
(es)
|
2011-08-03 |
2013-02-07 |
Salvador Moreno Rufino Baltasar |
Sistema de panel para construccion con retroiluminacion a base de diodos electroluminosos
|
EP2760845B1
(en)
|
2011-09-27 |
2016-11-16 |
Amgen Inc. |
Heterocyclic compounds as mdm2 inhibitors for the treatment of cancer
|
EA026827B1
(ru)
|
2011-10-14 |
2017-05-31 |
Медимьюн Лимитед |
Пирролбензодиазепины и их конъюгаты
|
US8969341B2
(en)
|
2011-11-29 |
2015-03-03 |
Novartis Ag |
Pyrazolopyrrolidine compounds
|
US9062071B2
(en)
|
2011-12-21 |
2015-06-23 |
Merck Sharp & Dohme Corp. |
Substituted piperidines as HDM2 inhibitors
|
WO2013105037A1
(pt)
|
2012-01-09 |
2013-07-18 |
Universidade Do Porto |
Inibidores da interação p53-mdm2
|
WO2013106646A2
(en)
|
2012-01-12 |
2013-07-18 |
Yale University |
Compounds and methods for the inhibition of vcb e3 ubiquitin ligase
|
CN104736569A
(zh)
|
2012-01-12 |
2015-06-24 |
耶鲁大学 |
通过e3泛素连接酶增强靶蛋白质及其他多肽降解的化合物和方法
|
JO3357B1
(ar)
|
2012-01-26 |
2019-03-13 |
Novartis Ag |
مركبات إيميدازوبيروليدينون
|
US8993614B2
(en)
|
2012-03-15 |
2015-03-31 |
F. Hoffmann-La Roche Ag |
Substituted pyrrolidine-2-carboxamides
|
AR091098A1
(es)
|
2012-05-21 |
2015-01-14 |
Genentech Inc |
ANTICUERPOS E INMUNOCONJUGADOS CONTRA Ly6E Y METODOS DE USO
|
US9365576B2
(en)
|
2012-05-24 |
2016-06-14 |
Novartis Ag |
Pyrrolopyrrolidinone compounds
|
SG11201406889WA
(en)
|
2012-05-30 |
2015-02-27 |
Hoffmann La Roche |
Substituted pyrrolidine-2-carboxamides
|
EP2888265B1
(en)
|
2012-08-23 |
2017-10-11 |
The Regents of The University of Michigan |
Bivalent inhibitors of iap proteins and therapeutic methods using the same
|
TWI586668B
(zh)
|
2012-09-06 |
2017-06-11 |
第一三共股份有限公司 |
二螺吡咯啶衍生物之結晶
|
JP6302912B2
(ja)
|
2012-09-19 |
2018-03-28 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
2−オキソ−2,3,4,5−テトラヒドロ−1h−ベンゾ[b]ジアゼピン及びがんの治療におけるその使用
|
DE102012018814A1
(de)
|
2012-09-24 |
2014-03-27 |
Glanzstoff Bohemia S.R.O. |
Garn mit Flammschutzwirkung und daraus gebildete textile Flächengebilde
|
CA2880324A1
(en)
|
2012-10-11 |
2014-04-17 |
F. Hoffmann-La Roche Ag |
Azaindolines
|
WO2014056755A1
(en)
|
2012-10-11 |
2014-04-17 |
F. Hoffmann-La Roche Ag |
Indolines
|
CN104640860B
(zh)
|
2012-10-11 |
2017-05-31 |
霍夫曼-拉罗奇有限公司 |
氮杂二氢吲哚
|
WO2014063061A1
(en)
|
2012-10-19 |
2014-04-24 |
Dana-Farber Cancer Institute, Inc. |
Hydrophobically tagged small molecules as inducers of protein degradation
|
GB201218862D0
(en)
|
2012-10-19 |
2012-12-05 |
Astex Therapeutics Ltd |
Bicyclic heterocycle compounds and their uses in therapy
|
TW201428002A
(zh)
|
2012-11-09 |
2014-07-16 |
必治妥美雅史谷比公司 |
用於抑制細胞凋亡抑制劑之巨環化合物
|
EP2917228A1
(en)
|
2012-11-09 |
2015-09-16 |
Ensemble Therapeutics Corporation |
Macrocyclic compounds for inhibition of inhibitors of apoptosis
|
WO2014082889A1
(en)
|
2012-11-28 |
2014-06-05 |
F. Hoffmann-La Roche Ag |
Novel imidazolines as dual inhibitors of mdm2 and mdmx
|
US9546174B2
(en)
|
2012-11-30 |
2017-01-17 |
Sanford-Burnham Medical Research Institute |
Inhibitor of apoptosis protein (IAP) antagonists
|
AU2013357493A1
(en)
|
2012-12-11 |
2015-04-30 |
F. Hoffmann-La Roche Ag |
Dimeric compounds
|
EP2934535B1
(en)
|
2012-12-20 |
2017-07-19 |
Merck Sharp & Dohme Corp. |
Substituted pyrrolopyrimidines as hdm2 inhibitors
|
MX2015008196A
(es)
|
2012-12-20 |
2015-09-16 |
Merck Sharp & Dohme |
Imidazopiridinas sustituidas como inhibidores de doble minuto 2 humana.
|
US9403827B2
(en)
|
2013-01-22 |
2016-08-02 |
Novartis Ag |
Substituted purinone compounds
|
EP2948453B1
(en)
|
2013-01-22 |
2017-08-02 |
Novartis AG |
Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the p53/mdm2 interaction
|
WO2014120748A1
(en)
|
2013-01-30 |
2014-08-07 |
Merck Sharp & Dohme Corp. |
2,6,7,8 substituted purines as hdm2 inhibitors
|
US9682978B2
(en)
|
2013-02-07 |
2017-06-20 |
Merck Sharp & Dohme Corp. |
2,6,7 substituted purines as HDM2 inhibitors
|
US20160002185A1
(en)
|
2013-02-19 |
2016-01-07 |
Amgen Inc. |
Cis-morpholinone and other compounds as mdm2 inhibitors for the treatment of cancer
|
US9805397B2
(en)
|
2013-03-01 |
2017-10-31 |
Google Inc. |
Auxiliary content suggestions relating to user generated content
|
WO2014151863A1
(en)
|
2013-03-14 |
2014-09-25 |
Amgen Inc. |
Heteroaryl acid morpholinone compounds as mdm2 inhibitors for the treatment of cancer
|
WO2014165506A1
(en)
*
|
2013-04-01 |
2014-10-09 |
Immunomedics, Inc. |
Anti-mucin antibodies for early detection and treament of pancreatic cancer
|
WO2014187777A1
(en)
|
2013-05-21 |
2014-11-27 |
Mediapharma S.R.L. |
Novel inhibitors of pvhl-elongin c binding
|
US8975417B2
(en)
|
2013-05-27 |
2015-03-10 |
Novartis Ag |
Pyrazolopyrrolidine derivatives and their use in the treatment of disease
|
JOP20200296A1
(ar)
|
2013-06-10 |
2017-06-16 |
Amgen Inc |
عمليات صنع وأشكال بلورية من mdm2 مثبط
|
DE102013215784A1
(de)
|
2013-06-12 |
2014-12-18 |
Schaeffler Technologies Gmbh & Co. Kg |
Fahrradantrieb und Fahrrad mit Fahrradantrieb
|
WO2015004610A1
(en)
|
2013-07-11 |
2015-01-15 |
Adamed Sp. Z O.O. |
1,5-dihydropyrrol-2-one derivatives as inhibitors of p53-mdm2/mdm4 protein-protein interaction
|
CA2918139A1
(en)
|
2013-08-12 |
2015-02-19 |
Genentech, Inc. |
1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment
|
US9278978B2
(en)
|
2013-08-23 |
2016-03-08 |
Boehringer Ingelheim International Gmbh |
6-Alkynyl Pyridine
|
US9249151B2
(en)
|
2013-08-23 |
2016-02-02 |
Boehringer Ingelheim International Gmbh |
Bis-amido pyridines
|
LT3068393T
(lt)
|
2013-11-11 |
2022-08-10 |
Amgen Inc. |
Kombinuota terapija, įskaitant mdm2 inhibitorių ir vieną arba daugiau papildomų farmaciškai aktyvių agentų, skirta vėžiui gydyti
|
BR112016008468A2
(pt)
*
|
2013-11-18 |
2017-10-03 |
Hoffmann La Roche |
Composto de fórmula, composição farmacêutica, composto, uso de um composto e método para o tratamento ou melhora de câncer
|
CA3178867A1
(en)
*
|
2013-11-27 |
2015-06-04 |
Redwood Bioscience, Inc. |
Hydrazinyl-pyrrolo compounds and methods for producing a conjugate
|
KR102354207B1
(ko)
|
2013-12-16 |
2022-01-20 |
제넨테크, 인크. |
펩티드모방체 화합물 및 그의 항체-약물 접합체
|
MX2016007851A
(es)
*
|
2013-12-16 |
2016-09-07 |
Genentech Inc |
Compuestos peptidomimeticos y conjugados anticuerpo-farmaco de estos.
|
EA201691023A1
(ru)
|
2013-12-16 |
2016-10-31 |
Дженентек, Инк. |
Пептидомиметические соединения и их конъюгаты антитела с лекарственным средством
|
EP3129380B1
(en)
|
2014-04-11 |
2018-11-28 |
Boehringer Ingelheim International Gmbh |
Spiro[3h-indole-3,2'-pyrrolidin]-2(1h)-one derivatives and their use as mdm2-p53 inhibitors
|
US20160058872A1
(en)
|
2014-04-14 |
2016-03-03 |
Arvinas, Inc. |
Imide-based modulators of proteolysis and associated methods of use
|
KR20210132233A
(ko)
|
2014-04-14 |
2021-11-03 |
아비나스 오퍼레이션스, 인코포레이티드 |
단백질분해의 이미드-기초된 조절인자 및 연관된 이용 방법
|
CN106458886A
(zh)
|
2014-04-15 |
2017-02-22 |
豪夫迈·罗氏有限公司 |
药物活性化合物的固体形式
|
SG11201608667SA
(en)
|
2014-04-17 |
2016-11-29 |
Univ Michigan |
Mdm2 inhibitors and therapeutic methods using the same
|
CA2950911C
(en)
|
2014-06-04 |
2023-10-10 |
Sanford-Burnham Medical Research Institute |
Use of inhibitor of apoptosis protein (iap) antagonists in hiv therapy
|
JP2017517555A
(ja)
|
2014-06-12 |
2017-06-29 |
アダムド エスピー.ゼット オー.オー.Adamed Sp.Z O.O. |
阻害剤p53−Mdm2タンパク質−タンパク質相互作用としての、1,1’,2,5’−テトラヒドロスピロ[インドール−3,2’−ピロール]−2,5’−ジオン系を含む化合物
|
JP6640126B2
(ja)
|
2014-06-27 |
2020-02-05 |
セルジーン コーポレイション |
セレブロン及び他のe3ユビキチンリガーゼの立体構造の変化を誘導するための組成物及び方法
|
US10576064B2
(en)
|
2014-07-03 |
2020-03-03 |
Boehringer Ingelheim International Gmbh |
Spiro[3H-indole-3,2′-pyrrolidin]-2(1H)-one compounds and derivatives as MDM2-P53 inhibitors
|
US10071164B2
(en)
*
|
2014-08-11 |
2018-09-11 |
Yale University |
Estrogen-related receptor alpha based protac compounds and associated methods of use
|
JP6625638B2
(ja)
|
2014-08-18 |
2019-12-25 |
ハドソン・バイオファーマ・インコーポレイテッド |
Mdm2阻害薬としてのスピロピロリジン
|
CA2956129C
(en)
|
2014-08-21 |
2022-10-25 |
Boehringer Ingelheim International Gmbh |
New spiro[3h-indole-3,2'-pyrrolidin]-2(1h)-one compounds and derivatives as mdm2-p53 inhibitors
|
CN107124870A
(zh)
*
|
2014-09-17 |
2017-09-01 |
基因泰克公司 |
包含抗her2抗体和吡咯并苯并二氮杂*的免疫缀合物
|
ES2858151T3
(es)
|
2016-05-20 |
2021-09-29 |
Hoffmann La Roche |
Conjugados de PROTAC-anticuerpo y procedimientos de uso
|